Multivariate analysis of prognostic factors in male breast cancer in Serbia

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 7, 2014, Pages 3233-3238

  Sipetic Grujicic, Sandra Branko ^a   Murtezani, Zafir Hajdar ^b   Neskovic Konstatinovic, Zora Borivoje ^c   Marinkovic, Jelena Milutin ^a   Kovcin, Vladimir Nikola ^b   Andric, Zoran Gojko ^b   Kostic, Sanja Vladeta ^b   Ratkov, Isidora Stojan ^a   Maksimovic, Jadranka Milutin ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Clinical Hospital Centre Bezanijska Kosa   (Serbia)

^c INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Breast cancer; Men; Predictors; Survival analysis

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; BREAST NEOPLASMS, MALE; CANCER STAGING; EPIDEMIOLOGY; HUMAN; LYMPH NODE METASTASIS; MALE; MASTECTOMY; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; SERBIA; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS, MALE; COMBINED MODALITY THERAPY; HUMANS; LYMPHATIC METASTASIS; MALE; MASTECTOMY, RADICAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SERBIA; SURVIVAL RATE; TAMOXIFEN;

EID: 84900859083     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.7.3233     Document Type: Article

References (41)

1. Agrawal A, Ayantunde A, Rampaul R, Robertson R (2007). Male breast cancer: a review of clinical management. Breast Cancer Res Treat, 103, 11-21.
2. Ahmadian M, Samah AA (2013). Application of health behavior theories to breast cancer screening among Asian women. Asian Pac J Cancer Prev, 14, 4005-13.
3. Auvien A, Curtis RE, Ron E (2002). Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst, 94, 1330-2.
4. Berg JW, Hutter RV (1995). Breast cancer. Cancer, 75, 257-69.
5. Bergmann A, Bello MA, Andrade Costa CR, et al (2012). Male breast cancer: overall survival in a single institution. J Clin Oncol, 30, 93.
6. Bruce DM, Heyes SD, Payne S (1996). Male breast cancer: clinicopathological features, immunocytochemical characteristics and prognosis. Eur J Surg Oncol, 22, 42-6.
7. Cimmino VM, Degnim AC, Sabel MS, et al (2004). Efficacy of sentinel lymph node biopsy in male breast cancer. J Surg Oncol, 86, 74-7.
8. Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H (2008). Male breast cancer: is the scenario changing. World J Surg Oncol, 6, 58-69.
9. D'Avanzo B, La Vecchia C (1995). Risk factors for male breast cancer. Br J Cancer, 71, 1359-62.
10. De Perrot M, Deleaval J, Robert J, Spiliopoulos A (2000). Thirtyyear experience of surgery for breast carcinoma in men. Eur J Surg, 166, 929-31.
11. Early Breast Cancer Trialist Collaborative group (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet, 365, 1687-717.
12. Foerster R, Foerster FG, WulffV, et al (2011). Matched-pair analysis of patients with female and male breast cancer: a comparative analysis. BMC Cancer, 11, 335-43.
13. Fentiman IS, Fourquet A, Hortobagyi GN (2006). Male breast cancer. Lancet, 367, 595-604.
14. Goldhirsch A, Wood WC, Coates AS, et al (2011). Panel members. Expert consensus on the primary therapy of early breast cancer. Ann Oncol, 22, 1736-47.
15. Goss PE, Reid C, Pintilie M, Lim R, Miller N (1999). Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years:1955-1996. Cancer, 85, 629-39.
16. Gomes-Raposo C, Zambrana Tevar F, Sereno Moyano M, Lopez Gomez M, Casado E (2010). Male breast cancer. Cancer Treat Rev, 36, 451-7.
17. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (2004). Breast carcinoma in men: a population-based study. Cancer, 101, 51-7.
18. Giordano SH, Perkins GH, Broglio K, et al (2005). Adjuvant systemic therapy for male breast carcinoma. Cancer, 104, 2359-64.
19. Guinee VF, Olsson H, Moller T, et al (1993). The prognosis of breast cancer in males. A report of 335 cases. Cancer, 71, 154-61.
20. Heller KS, Rosen PP, Schottenfeld D, Ashikari R, Kinne DW (1978). Male breast cancer: a clinicopathologic study of 97 cases. Ann Surg, 188, 60-5.
21. Joshi MG, Lee AK, Loda M, et al (1996). Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer, 77, 490-8.
22. Lanitis S, Rice AJ, Vaughan A, et al (2008). Diagnosis and management of male breast cancer. World J Surg, 32, 2471-6.
23. Mustafa IA, Cole B, Wanebo HJ, Bland KI, Chang HR (1998). Prognostic analysis of survival in small breast cancers. J Am Coll Surg, 186, 562-9.
24. Mahdi KM, Nassiri MR, Nasiri K (2013). Hereditary genes and SNPs associated with breast cancer. Asian Pac J Cancer Prev, 14, 3403-9.
25. Nahleh ZA, Srikantiah R, Safa M, et al (2007). Male breast cancer in the veterans affairs population: a comparative analysis. Cancer, 109, 1471-7.
26. Omer Fatih Olmez OF, Evrensel T, Cubukcu E, et al (2013). Prognostic significance of human epidermal receptor (HER)- 3 immunohistochemical expression in patients with metastatic breast cancer. Asian Pac J Cancer Prev, 14, 4115-9.
27. Ravandi-Kashani F, Hayes TG (1998). Male breast cancer: a review of the literature. Eur J Cancer, 34, 1341-7.
28. Ribeiro G, Swindell R (1992). Adjuvant tamoxifen for male breast cancer. Br J Cancer, 65, 252-4.
29. Ros JS, Fletcher JA, Linette GP, et al (2003). The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. The Oncologist, 8, 307-25.
30. Salvadori B, Saccozzi R, Manzari A, et al (1994). Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer, 30, 930-5.
31. Sasco AJ, Lowenfels AB, Pasker-de Jong P (1993). Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer, 53, 538-49.
32. Slamon D, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.
33. Schaub NP, Maloney N, Schneider H, Feliberti E, Perry R (2008). Changes in male breast cancer over a 30-year period. Am Surg, 74, 707-12.
34. Talluri S, Kakarala R, Karedan T, Kakarala M (2011). Male breast carcinoma in United States: survival rate and determinants of prognosis. J Clin Oncol, 29, 32.
35. Thompson D, Duedal S, Kirner J, et al (2005). Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst, 97, 813-22.
36. Volkers N (1999). In coping with cancer, gender metters. J Natl Canver Inst, 91, 1712-4.
37. Vaizey C, Burke M, Lange M (1999). Carcinoma of the male breast - a review of 91 patients from the Johannesburg Hospital breast clinics. S Afr J Surg, 37, 6-8.
38. Weiss JR, Moysich KB, Swede H (2005). Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev, 14, 20-6.
39. WolffAC, Hammond ME, Schwartz JN, et al. (2007). American society of clinical oncology/college of American pathologistsguideline recommendations for human growt factor receptor 2 testing in breast cancer. J Clin Oncol, 25, 118-45.
40. Xu CY, Jiang ZN, Zhou Y, Li JJ, Huang LM (2013). Estrogen receptor a roles in breast cancer chemoresistance. Asian Pac J Cancer Prev, 14, 4049-52.
41. Yildirim E, Berberoglu U (1998). Male breast cancer: a 22-year experience. Eur J Surg Oncol, 24, 548-52.